Log on early at 3:50 PM Pacific / 6:50 PM Eastern for the pre-webinar announcement segment that will include a brief interview with Dr. Olmstead.
Obesity, metabolic syndrome, and type 2 diabetes mellitus and associated disorders are a growing pandemic worldwide. Once simplistically thought to be the result of over eating and lack of physical activity, these abnormalities of metabolism are now known to be more complex. This presentation will review the mounting evidence that indicates the composition of the intestinal microbiota is significantly involved in controlling energy balance, body weight, and blood sugar and insulin control. Participants will learn how microorganisms play an important role in extracting energy from dietary fiber that humans cannot digest otherwise. We now know gut microbes produce bioactive substances that influence carbohydrate and fat metabolism, as well as keep inflammation in check. Efforts to link obese and lean body types with particular microbial populations have yielded conflicting results, but studies suggest obesity is associated with a reduced gut microbial diversity and diminished populations of Bifidobacterium and Lactobacillus. This presentation will foster an appreciation of the links between intestinal microorganisms and abnormal weight and sugar metabolism and provide further insights into how diet, probiotics, and prebiotics may be beneficially used in the setting of obesity, metabolic syndrome, and type 2 diabetes mellitus.
Stephen F. Olmstead, MD, is Chief Science Officer at ProThera, Inc. where he directs clinical trials of ProThera® and Klaire Labs™ nutraceutical products. He received his MD from the University of New Mexico in 1979 and completed his Internal Medicine residency at Harvard Medical School, Massachusetts General Hospital in 1982 and fellowship in Cardiovascular Diseases at the University of Washington in 1987. Dr. Olmstead served 2 years in the Commissioned Corps of the US Public Health and was stationed primary at the Indian Health Service Hospital in Gallup New Mexico. For many years, Dr. Olmstead spent his career as a Clinical Assistant Professor in Medicine at the University of Washington Medical School in Seattle. His current research focuses on the use of enzymes and chelating agents to disrupt pathogenic GI biofilm and pre- and probiotics to restore gut microbial balance.
To register for this webinar please click on the link below and follow the online registration instructions:
Stephen Olmstead, MD